Skip to content

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Hormone Therapy

1. to investigate the association between route of administration of exogenous estrogen (transdermal vs. oral) and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) women.
2. to investigate the association between exogenous testosterone exposure and cardiorenal risk in cisgender (gender identity aligning with sex at birth) and transgender (gender identity not aligning with sex at birth) men.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 to 90

Critères de participation

Inclusion Criteria:

* Age 18 to 90 years
* Taking hormones orally or non-orally (either estrogen, progesterone or testosterone)

Exclusion Criteria:

* Cardiovascular disease (symptoms consistent with myocardial ischemia, previously documented myocardial ischemia, cardiac arrhythmias or valve abnormalities, or abnormal ECG at screening)
* Cerebrovascular disease (transient ischemic attacks or stroke)
* History of hypertension (BP\>140/90 or use of antihypertensive medications)
* Estimated glomerular filtration rate (eGFR) \< 60 ml/min/1.73m2
* Diabetes mellitus (defined by history, use of hypoglycaemic agents or a fasting glucose \>7mmol/L)
* Current smoker
* Previous history of preeclampsia
* Anabolic steroids, cortical steroids, or non-steroidal anti-inflammatory medications, or at the discretion of the investigator.

Lieu de l'étude

University of Calgary
University of Calgary
Calgary, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Darlene Y Sola, BScN

[email protected]
4036149431
Backup Contact

Victoria Riehl-Tonn, BN

[email protected]
4036149431
Étude parrainée par
University of Calgary
Participants recherchés
Plus d'informations
ID de l'étude: NCT05442463